Skip to main content

Table 2 The utilization of each biologic and non-biologic drug

From: Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia

Medication

CD (N = 258)

UC (N = 249)

P-value

Total (N = 507)

Biological agent, n (%)

 

 Infliximab

95 (36.82)

28 (11.24)

< 0.01*

123 (24.26)

 Adalimumab

53 (20.54)

24 (9.64)

< 0.01*

77 (15.19)

 Certolizumab

6 (2.33)

0

0.03

6 (1.18)

 Golimumab

0

1 (0.40)

0.49

1 (0.20)

 Ustekinumab

4 (1.55)

0

0.12

4 (0.79)

 Vedolizumab

2 (0.78)

2 (0.80)

1

4 (0.79)

Non-biological agents, n (%)

 

 Azathioprine

185 (71.71)

100 (40.16)

< 0.01*

285 (56.21)

 Mercaptopurine

0

3 (1.20)

0.12

3 (0.59)

 Methotrexate

7 (2.71)

0

0.02

7 (1.38)

 Sulfasalazine

3 (1.16)

3 (1.20)

1

6 (1.18)

 Mesalazine

37 (14.34)

208 (83.53)

< 0.01*

245 (48.32)

 Prednisone

0

0

–

0

 Prednisolone

6 (2.33)

12 (4.82)

0.13

18 (3.55)

 Hydrocortisone

3 (1.16)

3 (1.20)

1

6 (1.18)

 Budesonide

9 (3.49)

0

0.01*

9 (1.78)

 Corticosteroids

18 (6.98)

15 (6.02)

0.66

33 (6.51)

 Metronidazole

12 (4.65)

4 (1.61)

0.03*

16 (3.16)

 Ciprofloxacin

5 (1.94)

4 (1.60)

0.45

9 (1.78)

  1. *Indicates statistically significant difference